Cell Therapies

What Cell Therapies does

Cell Therapies Pty Ltd (CTPL) is an Australian contract development and manufacturing organization (CDMO) founded in 2003 and headquartered in Melbourne, specializing in cell and gene therapies (CGT). The company is majority owned by Peter MacCallum Cancer Centre and is physically co-located on the Peter Mac campus, which provides privileged access to clinical infrastructure and translational research. Its core offering covers process development, GMP manufacturing, and release testing across autologous and allogeneic cell therapies, including CAR-T, iPSC-derived, and other advanced therapy modalities. The facility operates 13 GMP cleanrooms with capacity of up to 2,000 patient doses per year following a 2023 commercial-scale expansion.

The company serves a customer base split between large pharmaceutical sponsors (notably Novartis for commercial Kymriah manufacturing and BioNTech for BNT211) and a long tail of clinical-stage Australian and APAC biotechs (Arovella, Carina Biotech, AdAlta, Chimeric, Skin2Neuron, A-SEEDS, ENCell, and others). It generates revenue through fee-for-service manufacturing contracts, milestone-based process development engagements, and long-term commercial supply agreements. Regulatory coverage spans TGA, FDA, EMA, PMDA, MFDS, and HSA, making Cell Therapies one of a small number of Asia-Pacific CDMOs qualified to ship to all major CGT markets.

Operationally, the company has signaled an intentional shift from a domestic Peter Mac-anchored service model toward a broader APAC growth strategy, formalized as the Asia Pacific Alliance Model (APAM). Recent partnerships with ENCell (Korea, December 2025), ACTRIS (Singapore, February 2026), and Teijin (Japan), alongside a collaboration with Ori Biotech on automated IRO platform integration, point to a deliberate build-out of cross-border manufacturing capacity and technology ecosystem reach. The October 2023 appointment of Dr Bev Menner as CEO marked a transition toward commercially oriented leadership to execute this expansion.

Name

Cell Therapies

Legal name

Cell Therapies Pty Ltd

Website

https://celltherapies.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Cell Therapy CDMO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

akta.pro secondary industries

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

Keywords

• Cell therapy CDMO
• GMP manufacturing services
• Cell and gene therapy
• CAR-T manufacturing
• Biopharmaceutical contract manufacturing

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Manufacturing Services: Fee-for-service CDMO model providing GMP manufacturing, technology transfer, process development, analytical testing, quality management, and clinical trial support services to biotech and pharmaceutical clients.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Cell Therapies is an Australian-based Contract Development and Manufacturing Organization (CDMO) providing integrated, phase-appropriate GMP manufacturing of cell and gene therapies from preclinical concept through commercial supply. Its service portfolio spans contract GMP manufacturing, technology transfer, process development, analytical testing, quality as a service, consulting and advisory, clinical trial support, cryopreservation and logistics, and digitalisation and automation. The company manufactures autologous and allogeneic cell therapy products including CAR-T cells, mesenchymal stromal cells, tumour-infiltrating lymphocytes (TILs), and human pluripotent stem cells and their derivatives.

Product overview

Cell Therapies is a Contract Development and Manufacturing Organization (CDMO) providing integrated, end-to-end GMP manufacturing services for cell therapies, ex-vivo gene therapies, and regenerative medicine products. Their service portfolio spans from preclinical concept through commercial supply, including Contract GMP Manufacturing, Technology Transfer, Process Development, Analytical Testing and Development, Quality as a Service, Consulting and Advisory, Clinical Trial Support, Cryopreservation & Logistics, and Digitalisation & Automation. They specialize in CAR-T cells, mesenchymal stromal cells, tumor-infiltrating lymphocytes (TILs), and human pluripotent stem cells, with regulatory licenses from TGA, FDA, PMDA, EMA, MFDS, and HSA.

Differentiator

Problem solved

Functional benefit

Named customers10 records

Segments4 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Skin2NeuroncoreStrategic or Co-development Partner · 15 May 2026Manufacturing agreement for Skin2Neuron's lead autologous neurorestorative cell therapy for Phase 1 clinical trials. Cell Therapies provides process transfer, GMP manufacturing, scale-up and quality release services for hair follicle-derived neuroprecursor (HFN) cells targeting Alzheimer's disease and neurodegenerative conditions. Both companies are members of SmartCRC.
• AdAltacoreStrategic or Co-development Partner · 29 April 2026Manufacturing work order for AdAlta's lead CAR-T program BZDS1901, a first-in-class therapy targeting mesothelioma. Supports AdAlta's 'East to West' strategy to deliver scalable, cost-effective cell therapies for solid cancers for global markets. Previously established Master Services Agreement making Cell Therapies preferred manufacturer of AdAlta's cellular immunotherapies.
• Ori BiotechcoreTechnology or Integration · 21 April 2026Collaboration with Ori Biotech and AdAlta to deploy Ori Biotech's automated cell therapy manufacturing platform IRO in Asia Pacific and across AdAlta's cellular immunotherapy pipeline. Positions AdAlta and Cell Therapies as leaders in advanced cell therapy manufacturing in Asia-Pacific.
• ACTRIScoreStrategic or Co-development Partner · 11 February 2026MoU with Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) to strengthen ACTRIS's position as a premier CGT manufacturing hub in Asia. Collaboration aims to optimize GMP-compliant manufacturing processes, enable efficient technology transfer and scale-up, strengthen regulatory strategy, and build long-term infrastructure and workforce capability through training and development initiatives. Part of Cell Therapies' Asia Pacific Alliance Model (APAM).
• ENCellcoreStrategic or Co-development Partner · 5 December 2025Strategic APAC partnership with Korea-based ENCell Co., Ltd. Collaboration across four core areas: CGT manufacturing and process development optimization, regulatory alignment across Korea, Australia, Japan, and broader APAC, joint market engagement for APAC expansion, and workforce development including training programs and research initiatives for iPSC platforms and allogeneic therapies.
• A-SEEDScoreStrategic or Co-development Partner · 19 November 2025Manufacturing partnership for ACS2015 CAR-T therapy targeting EPHB4-positive solid tumours. ACS2015 being evaluated in Phase I/Ib CARTiEr E312 study for colorectal cancer, hepatocellular carcinoma, and bone/soft tissue sarcomas. Cell Therapies responsible for GMP manufacture for Australian patients.
• TeijincoreStrategic or Co-development Partner · 30 September 2025Strategic collaboration to expand access to advanced cell and gene therapies in Japan and the Asia Pacific region.
• Viral Vector Manufacturing Facility (VVMF)minorStrategic or Co-development Partner · 16 July 2025Strategic collaboration with Viral Vector Manufacturing Facility Pty. Ltd. for viral vector manufacturing capabilities.
• Xellera TherapeuticscoreStrategic or Co-development Partner · 1 April 2025MoU with Xellera Therapeutics to fast-track CGT access across APAC. Strategic partnership to accelerate patient access to cell and gene therapies.
• Chimeric TherapeuticsminorStrategic or Co-development Partner · 9 August 2024Partnership to explore manufacturing Chimeric's CAR-T assets in Australia. Chimeric is a clinical stage cell therapy company focused on autologous CAR-T and allogeneic NK cell therapies with 4 clinical stage programs across oncology.
• AdAlta/AdCellacoreStrategic or Co-development Partner · 12 May 2024Master Services Agreement establishing Cell Therapies as AdAlta's preferred manufacturer of cellular immunotherapies. Provides AdCella (AdAlta's collaboration with SYNthesis BioVentures) with access to deep experience in development and manufacturing of cellular immunotherapies and state-of-the-art facilities. Initial work includes Technical Feasibility Assessments of AdCella's in-licensing candidates.
• Arovella TherapeuticscoreStrategic or Co-development Partner · 8 November 2023Partnership to develop Arovella's ALA-101 manufacturing process for cancer clinical trials. ALA-101 incorporates Arovella's invariant Natural Killer T (iNKT) cell therapy platform combined with CAR targeting CD19 for allogeneic treatment of CD19-expressing blood cancers. Cell Therapies to further develop proprietary CAR-iNKT manufacturing process to meet Phase 1 clinical trial requirements.
• BioNTechcoreStrategic or Co-development Partner · 21 September 2022Engaged by BioNTech to manufacture BNT211, a novel CAR-T cell therapy candidate for relapsed or refractory advanced solid tumours. Cell Therapies establishing clinical trial product supply chain in Australia utilizing extensive CAR-T manufacturing experience. Part of BioNTech-sponsored global Phase 1/2 clinical trial.
• Carina BiotechcoreStrategic or Co-development Partner · 31 May 2022Partnership to manufacture Carina Biotech's CAR-T cell therapy for patients with colorectal cancer. Carina's leading CAR-T candidate targets the cancer stem cell marker LGR5 and has shown promising pre-clinical results. Highlights sovereign capability to develop breakthrough products from research concept to clinical application.
• NovartiscoreStrategic or Co-development Partner · 28 January 2020Manufacturing agreement for Kymriah (tisagenlecleucel) CAR-T therapy, enabling first Australian on-shore commercial manufacture and supply. Previously, Australian patients had blood collected and sent overseas for manufacturing. Agreement marked significant milestone for Australian patients requiring CAR-T treatment.
• PharmaBiominorStrategic or Co-development Partner · 28 April 2015Alliance to deliver pan-Asian cell processing capability for regenerative medicine and cellular therapy industry.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Genezen: Genezen is a US-based emerging cell and gene therapy CDMO offering viral vector and cell therapy manufacturing services, representing a newer specialized competitor targeting similar early-stage biotech customers as Cell Therapies.

Direct peers

• RoslinCT: RoslinCT is a Scottish cell therapy CDMO specializing in GMP manufacturing of cell-based therapies including CAR-T, iPSC, and MSC products, providing a comparable specialized cell therapy manufacturing service to biotech clients as Cell Therapies.
• Yposkesi: Yposkesi is a French cell and gene therapy CDMO offering GMP manufacturing of viral vectors and cell therapy products, providing a comparable specialized European CDMO alternative competing for similar biotech customers.
• Resilience: Resilience is a US-based cell and gene therapy CDMO with multiple GMP manufacturing facilities offering autologous and allogeneic cell therapy production services comparable to Cell Therapies' core CDMO offering, competing for similar biotech clients.
• AGC Biologics: AGC Biologics is a global CDMO with dedicated cell and gene therapy GMP manufacturing services including autologous and allogeneic cell therapy production, viral vector, and process development, making it a direct competitor to Cell Therapies for clinical and commercial contracts.

Broad incumbents

• Lonza: Lonza is the world's largest cell and gene therapy CDMO operating multiple global GMP facilities offering autologous and allogeneic cell therapy manufacturing, viral vector production, and process development services directly comparable to Cell Therapies' core offering.
• Catalent: Catalent (now part of Novo Holdings) operates global cell therapy manufacturing facilities in the US and Europe providing GMP production of autologous and allogeneic cell therapies, with comparable CAR-T and gene-edited cell therapy capabilities to Cell Therapies.
• Samsung Biologics: Samsung Biologics is a major Korean-based CDMO with growing cell and gene therapy manufacturing services, providing a comparable APAC-anchored CDMO alternative to Cell Therapies with much larger capacity and broader service portfolio.
• Thermo Fisher Scientific (Patheon Pharma Services): Thermo Fisher's pharma services division offers cell therapy and biologics manufacturing capabilities as part of a much broader CDMO portfolio, providing overlapping services to biotech clients and competing for late-phase and commercial cell therapy contracts.
• Charles River Laboratories: Charles River Laboratories offers cell therapy manufacturing and process development services through its CDMO segment, providing comparable GMP manufacturing, viral vector, and analytical services with broader portfolio including preclinical research capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CellTherapies_
• LinkedInlinkedin.com/company/cell-therapies-pty-ltd
• Facebookfacebook.com/CellTherapies

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell Therapies